Home » Newsletters » BioWorld Science

BioWorld Science

July 7, 2004

View Archived Issues

Nuvelo reports preliminary data from phase II study of alfimeprase in PAO

Preliminary data on long-term rosiglitazone for Cushing's disease

Subcutaneous TH-9507 shows promise for chronic wasting conditions

LY-156735 found effective and safe in primary insomnia

Potential benefits of BW-755C in metabolic dysfunction caused by high fructose diet in rats

Novartis seeks European approval of Xolair for severe allergic asthma

Canadian approval for initiation of phase II study of I.E.T. for MS

Approvable letter for Agilect in Parkinson's disease

Indaflex demonstrates significant localized antiinflammatory activity

Provalis signs vaccine option agreement with Chiron Vaccines

GlaxoSmithKline renews Crucell PER.C6 license agreement

Nymox pursues new approaches to combating Alzheimer's disease

Phosmidosine derivatives with antitumor activity presented by Sankyo

Solvay researchers describe series of 5-HT3 receptor antagonists

Aventis Pharma scientists design new protein kinase inhibitors

Boehringer Ingelheim presents compounds for inflammatory and obstructive airways diseases

Cadila claims aralkyl derivatives as antidiabetic, hypolipidemic and hypocholesterolemic compounds

Antifungal triazole prodrugs described in Sankyo patent

First description of lipoptosis using IgM antibody SAM-6

Tropical plant derivative induces mitochondria-dependent apoptosis in vitro

PARG inhibitor effective in vivo in septic shock-like syndrome, PARG may be novel therapeutic target

HKI-272 shows promise in the treatment of HER-2-positive tumors

Greater patient satisfaction achieved with inhaled insulin over subcutaneous insulin in diabetes

Patent claims new method to treat GI disorders with duloxetine

PROactive trial evaluates cardiovascular effects of pioglitazone in diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...